To investigate the association between TyG levels in early and mid-pregnancy, including their dynamic differences, and the risk of developing gestational diabetes mellitus (GDM).
Approach:
Study Design: A prospective cohort study was conducted with 870 pregnant women.
Data Analysis: Univariate Cox regression was used to screen variables, followed by multivariate Cox proportional hazards regression to analyze associations.
Key Findings:
119 out of 870 participants developed GDM, resulting in an incidence rate of 13.68%.
Elevated TyG levels in early and mid-pregnancy, along with a greater percentage increase in TyG levels, were identified as independent risk factors for GDM after adjusting for confounding factors.
Elevated TyG levels in mid-pregnancy posed the highest risk for developing GDM.
Interpretation:
Elevated TyG indices during early and mid-pregnancy, as well as a progressive increase in TyG levels, are significant indicators for assessing GDM risk.
Limitations:
The study may not account for all potential confounding factors influencing GDM risk.
Generalizability may be limited to the specific population studied.
Conclusion:
The findings support the use of TyG levels as a reference for evaluating GDM risk.
Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.
